Testing a new combo for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug (ES102) combined with an immunotherapy (Toripalimab) for people with advanced non-small cell lung cancer that has stopped responding to standard treatments. It may help those whose tumors have high PD-L1 levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced non-small cell lung cancer that cannot be removed by surgery and has progressed after chemotherapy and immunotherapy.
- Your tumor does not have certain gene changes (EGFR, ALK, or ROS1).
- Your tumor has high PD-L1 levels (at least 50% by a special test).
- You are in good enough health to get out of bed and take care of yourself (ECOG 0 or 1).
- You have not had treatment targeting OX40 before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests whether a new drug combination (SYS6010 plus enlonstobart) works better than standard immunotherapy with chemotherapy for patients with advanced non-small cell lung cancer. You may qualify if you have not received prior cancer treatment and have a specific marker (PD-L1) on your tumor.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a new combination treatment for people with advanced non-small cell or small cell lung cancer that cannot be removed by surgery or cured with standard treatments. It aims to see if the combination is safe and effective.
This trial tests a new investigational drug combined with chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if it is safe and works better than current treatments.
This trial tests an experimental immunotherapy called BNT116, given alone or with other drugs, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if it is safe and if it can help shrink tumors.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.